United Therapeutics Corp (UTHR)
274.26
+2.04
(+0.75%)
USD |
NASDAQ |
May 17, 16:00
274.29
+0.03
(+0.01%)
Pre-Market: 20:00
United Therapeutics Enterprise Value: 10.06B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 10.06B |
May 16, 2024 | 9.970B |
May 15, 2024 | 9.991B |
May 14, 2024 | 9.861B |
May 13, 2024 | 9.620B |
May 10, 2024 | 9.617B |
May 09, 2024 | 9.696B |
May 08, 2024 | 9.476B |
May 07, 2024 | 9.703B |
May 06, 2024 | 9.450B |
May 03, 2024 | 9.534B |
May 02, 2024 | 9.345B |
May 01, 2024 | 9.212B |
April 30, 2024 | 8.289B |
April 29, 2024 | 8.463B |
April 26, 2024 | 8.265B |
April 25, 2024 | 8.358B |
April 24, 2024 | 8.405B |
April 23, 2024 | 8.286B |
April 22, 2024 | 8.268B |
April 19, 2024 | 8.440B |
April 18, 2024 | 8.395B |
April 17, 2024 | 8.324B |
April 16, 2024 | 8.167B |
April 15, 2024 | 8.313B |
Date | Value |
---|---|
April 12, 2024 | 8.174B |
April 11, 2024 | 8.379B |
April 10, 2024 | 8.404B |
April 09, 2024 | 8.370B |
April 08, 2024 | 8.367B |
April 05, 2024 | 8.217B |
April 04, 2024 | 8.233B |
April 03, 2024 | 8.112B |
April 02, 2024 | 7.996B |
April 01, 2024 | 7.982B |
March 31, 2024 | 8.047B |
March 28, 2024 | 8.516B |
March 27, 2024 | 9.154B |
March 26, 2024 | 9.370B |
March 25, 2024 | 9.200B |
March 22, 2024 | 8.901B |
March 21, 2024 | 8.855B |
March 20, 2024 | 8.846B |
March 19, 2024 | 8.972B |
March 18, 2024 | 8.716B |
March 15, 2024 | 8.801B |
March 14, 2024 | 8.911B |
March 13, 2024 | 9.060B |
March 12, 2024 | 9.323B |
March 11, 2024 | 9.447B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.554B
Minimum
Jul 22 2019
10.97B
Maximum
Dec 09 2022
6.781B
Average
7.610B
Median
Enterprise Value Benchmarks
Liquidia Corp | 812.97M |
Ligand Pharmaceuticals Inc | 1.235B |
Esperion Therapeutics Inc | 482.55M |
Vertex Pharmaceuticals Inc | 104.72B |
ANI Pharmaceuticals Inc | 1.360B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 306.60M |
Revenue (Quarterly) | 677.70M |
Total Expenses (Quarterly) | 321.40M |
EPS Diluted (Quarterly) | 6.17 |
Gross Profit Margin (Quarterly) | 89.24% |
Profit Margin (Quarterly) | 45.24% |
Earnings Yield | 7.71% |
Operating Earnings Yield | 9.22% |
Normalized Earnings Yield | 7.712 |